论文部分内容阅读
目的观察硫普罗宁联合血脂康治疗酒精性脂肪肝的临床疗效。方法将120例酒精性脂肪肝患者随机分为治疗组与对照组,治疗组(65例)予硫普罗宁(2片,3次/d)口服、血脂康(2粒,2次/d)口服,对照组予东宝肝泰片(4片,3次/d)口服,疗程3个月。结果治疗组与对照组疗效对比经统计学处理差异有显著性(P<0.01),治疗后各项指标复查情况对比,经统计学处理两组差异均有显著性。结论硫普罗宁联合血脂康确有保护肝细胞,改善肝功能,显著缓解临床症状的作用,特别适用于酒精性脂肪肝的患者。
Objective To observe the clinical efficacy of tiopronin combined with Xuezhikang in the treatment of alcoholic fatty liver disease. Methods 120 patients with alcoholic fatty liver were randomly divided into treatment group and control group. The treatment group (65 patients) was given tiopronin (2 tablets, 3 times / d) orally, and Xuezhikang (2 tablets, 2 times / d) Oral, the control group to Dongbao liver tablets (4 tablets, 3 times / d) orally, the course of 3 months. Results The curative effect of the treatment group and the control group was statistically significant (P <0.01). After the treatment, the comparison of the indexes was significant. There was significant difference between the two groups by statistical analysis. Conclusion The combination of tiopronin and Xuezhikang does have the function of protecting liver cells, improving liver function and relieving the clinical symptoms remarkably, and is especially suitable for patients with alcoholic fatty liver.